Your browser is no longer supported. Please, upgrade your browser.
Pluristem Therapeutics Inc.
Index- P/E- EPS (ttm)-1.76 Insider Own10.00% Shs Outstand31.64M Perf Week3.86%
Market Cap92.74M Forward P/E- EPS next Y-0.31 Insider Trans-23.37% Shs Float27.70M Perf Month0.68%
Income-49.90M PEG- EPS next Q-0.41 Inst Own14.10% Short Float1.29% Perf Quarter-24.68%
Sales0.00M P/S- EPS this Y-10.70% Inst Trans-29.21% Short Ratio1.58 Perf Half Y-43.62%
Book/sh1.81 P/B1.64 EPS next Y5.40% ROA-70.30% Target Price- Perf Year-69.83%
Cash/sh2.07 P/C1.43 EPS next 5Y- ROE-92.60% 52W Range2.81 - 11.85 Perf YTD-58.13%
Dividend- P/FCF- EPS past 5Y9.50% ROI- 52W High-74.77% Beta2.30
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin- 52W Low6.41% ATR0.15
Employees129 Current Ratio5.80 Sales Q/Q- Oper. Margin- RSI (14)47.21 Volatility4.35% 4.54%
OptionableYes Debt/Eq0.42 EPS Q/Q-33.90% Profit Margin- Rel Volume0.58 Prev Close2.96
ShortableYes LT Debt/Eq0.42 Earnings- Payout- Avg Volume226.29K Price2.99
Recom2.00 SMA20-0.23% SMA50-5.95% SMA200-39.29% Volume35,902 Change1.01%
May-04-21Initiated Alliance Global Partners Buy $12.50
Dec-10-20Downgrade Jefferies Buy → Hold $6
Jun-19-20Initiated Jefferies Buy $12
Dec-16-19Initiated Dawson James Buy $12
Jul-22-19Initiated Ladenburg Thalmann Buy
Feb-13-17Downgrade Maxim Group Buy → Hold
Jul-19-16Resumed H.C. Wainwright Buy $3.50
Dec-22-15Reiterated Maxim Group Buy $8 → $3
Feb-03-15Reiterated Needham Buy $5 → $4
Sep-22-14Resumed Oppenheimer Outperform
Sep-08-14Initiated H.C. Wainwright Buy $4
Jan-21-14Reiterated MLV & Co Buy $4.50 → $6
Sep-16-13Upgrade Maxim Group Hold → Buy $8
Jun-04-13Downgrade Maxim Group Buy → Hold
May-31-13Initiated MLV & Co Buy $4.50
Jul-25-12Initiated Maxim Group Buy $8
Jul-24-12Downgrade WBB Securities Speculative Buy → Hold $4 → $3.75
May-22-12Initiated Needham Buy $5
Dec-09-11Initiated Global Hunter Securities Speculative Buy $5
Jun-17-11Initiated Dawson James Buy $5
Sep-22-21 08:15AM  
Sep-01-21 11:01AM  
Aug-24-21 11:32AM  
Jul-19-21 07:00AM  
Jul-08-21 07:10AM  
Jun-21-21 08:04AM  
May-25-21 08:48AM  
Apr-29-21 09:42AM  
Apr-04-21 09:12PM  
Mar-05-21 02:52AM  
Feb-02-21 08:30AM  
Jan-27-21 07:00AM  
Jan-06-21 07:00AM  
Jan-04-21 02:52AM  
Dec-29-20 07:00AM  
Dec-09-20 07:23AM  
Dec-02-20 03:52PM  
Nov-18-20 07:00AM  
Nov-03-20 10:57AM  
Oct-20-20 07:00AM  
Oct-14-20 08:38AM  
Oct-13-20 07:00AM  
Oct-07-20 07:30AM  
Oct-01-20 03:00AM  
Sep-15-20 07:30AM  
Sep-14-20 03:15PM  
Aug-27-20 07:00AM  
Aug-20-20 09:46AM  
Aug-19-20 07:00AM  
Aug-17-20 09:09AM  
Aug-10-20 08:44AM  
Jul-21-20 07:10AM  
Jun-23-20 09:24PM  
Jun-11-20 07:00AM  
Jun-05-20 04:05PM  
Jun-03-20 07:00AM  
Jun-01-20 11:30AM  
May-15-20 11:30AM  
May-14-20 08:00AM  
May-08-20 07:59AM  
May-05-20 09:56AM  
Apr-30-20 12:00PM  
Apr-29-20 11:30AM  
Apr-28-20 06:40AM  
Apr-27-20 06:00AM  
Apr-24-20 08:38AM  
Apr-23-20 03:05PM  
Apr-17-20 06:00AM  
Apr-15-20 08:35AM  
Apr-14-20 03:59PM  
Apr-13-20 06:00AM  
Apr-10-20 11:38AM  
Apr-09-20 08:32AM  
Apr-08-20 12:58PM  
Apr-07-20 07:50AM  
Mar-30-20 07:30AM  
Mar-26-20 08:00AM  
Mar-21-20 10:31AM  
Mar-17-20 08:47AM  
Mar-12-20 09:00AM  
Mar-03-20 07:00AM  
Feb-10-20 07:00AM  
Feb-03-20 07:00AM  
Jan-09-20 11:53AM  
Dec-17-19 07:00AM  
Dec-11-19 06:40AM  
Dec-03-19 07:00AM  
Nov-30-19 11:40AM  
Nov-19-19 11:06AM  
Nov-12-19 07:00AM  
Nov-04-19 07:00AM  
Oct-28-19 11:16AM  
Oct-08-19 02:00PM  
Sep-16-19 12:20PM  
Sep-09-19 07:00AM  
Sep-05-19 09:24AM  
Aug-21-19 07:00AM  
Jul-31-19 08:00AM  
Jul-25-19 07:21AM  
Jul-24-19 10:45AM  
Jul-22-19 09:33AM  
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 28Sale3.72115,007427,8263,121,918Jun 01 07:34 AM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 27Sale3.6995,885353,8163,236,925Jun 01 07:34 AM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 26Sale3.68144,678532,6353,332,810Jun 01 07:34 AM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 25Sale3.84261,2381,003,1543,477,488May 27 06:15 AM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 24Sale3.8379,300303,7193,738,726May 27 06:15 AM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 21Sale3.9869,838277,9553,818,026May 27 06:15 AM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerMay 03Sale4.2823,721101,5263,887,864May 04 04:06 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerApr 30Sale4.66166,004773,5793,911,585May 04 04:06 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerNov 30Buy9.7020,000194,0004,077,589Dec 01 04:10 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerOct 30Buy9.5150,000475,5004,057,589Nov 03 04:51 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerOct 29Buy9.2020,000184,0004,007,589Oct 29 04:27 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerSep 30Buy10.34139,0061,437,3223,987,589Oct 01 04:12 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerSep 29Buy9.7660,123586,8003,848,583Oct 01 04:12 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerSep 28Buy9.4913,189125,1643,788,460Sep 29 04:05 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerSep 24Buy9.0234,800313,8963,775,271Sep 25 04:10 PM
CLOVER WOLF CAPITAL - LIMITED 10% OwnerSep 23Buy9.0410,73496,9833,740,471Sep 24 04:33 PM